🔴 Humacyte is trading 6.1% down today on profit-taking after FDA trial clearance spike

Humacyte is trading 6.1% down at $0.63 as investors lock in gains following a sharp rally triggered by the FDA's clearance of its Investigational New Drug application.

• The recent price surge was driven by the FDA clearing a Phase 2a trial for the company's bioengineered coronary tissue engineered vessel.
• Today's pullback likely reflects consolidation and profit-taking after the significant company-specific catalyst.
• The downward move appears isolated to Humacyte, as the broader biotechnology sector is currently trading higher.